
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:04:14 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638 | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638"/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/32/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638"/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/32/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../../covid-19.hbs.hu/index.html" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/322679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">1250</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="32">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="32">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/k1J"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=IC_BPS%20and%20glycosaminoglycans%20replacement%20therapy%202015%20tau-04-06-638&amp;url=https://hbs.hu/r/k1J"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/k1J&amp;title=IC_BPS%20and%20glycosaminoglycans%20replacement%20therapy%202015%20tau-04-06-638&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/k1J"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/32?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="32" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>5. 642 Cervigni. IC/BPS and glycosaminoglycans replacement therapy Transl Androl Urol  2015;4(6):638-642 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. Urol 1987;138:503-7. 18.   Nickel JC, Barkin J, Forrest J, et al. Randomized, double- blind, dose-ranging study of pentosan polysulfate sodium  for interstitial cystitis. Urology 2005;65:654-8.  19.   Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline  for the diagnosis and treatment of interstitial cystitis/ bladder pain syndrome. J Urol 2011;185:2162-70. 20.   Morales A, Emerson L, Nickel JC, et al. Intravesical  hyaluronic acid in the treatment of refractory interstitial  cystitis. J Urol 1996;156:45-8. 21.   Parsons CL, Lilly JD, Stein P. Epithelial dysfunction  in nonbacterial cystitis (interstitial cystitis). J Urol  1991;145:732-5. 22.   Rooney P, Srivastava A, Watson L, et al. Hyaluronic acid  decreases IL-6 and IL-8 secretion and permeability in an  inflammatory model of interstitial cystitis. Acta Biomater  2015;19:66-75. 23.   Gupta SK, Pidcock L, Parr NJ. The potassium sensitivity  test: a predictor of treatment response in interstitial  cystitis. BJU Int 2005;96:1063-6. 24.   Kallestrup EB, Jorgensen SS, Nordling J, et al. Treatment  of interstitial cystitis with Cystistat: a hyaluronic acid  product. Scand J Urol Nephrol 2005;39:143-7. 25.   Riedl CR, Engelhardt PF, Daha KL, et al. Hyaluronan  treatment of interstitial cystitis/painful bladder syndrome.  Int Urogynecol J Pelvic Floor Dysfunct 2008;19:717-21. 26.   Engelhardt PF, Morakis N, Daha LK, et al. Long-term  results of intravesical hyaluronan therapy in bladder  pain syndrome/interstitial cystitis. Int Urogynecol J  2011;22:401-5. 27.   Hanno P, Baranowski A, Fall M, et al. Painful bladder  syndrome (including interstitial cystitis). In: Abrams PH,  Wein AJ, Cardozo L, et al, editors. Incontinence. 3rd  edition. Paris: Health Publications Limited, 2005:1456-520. 28.   Daha LK, Riedl CR, Lazar D, et al. Do cystometric  findings predict the results of intravesical hyaluronic acid in  women with interstitial cystitis? Eur Urol 2005;47:393-7;  discussion 397. 29.   Lv YS, Zhou HL, Mao HP, et al. Intravesical hyaluronic  acid and alkalinized lidocaine for the treatment of  severe painful bladder syndrome/interstitial cystitis. Int  Urogynecol J 2012;23:1715-20. 30.   Steinhoff G, Ittah B, Rowan S. The efficacy of chondroitin  sulfate 0.2% in treating interstitial cystitis. Can J Urol  2002;9:1454-8. 31.   Nickel JC, Egerdie B, Downey J, et al. A real-life  multicentre clinical practice study to evaluate the efficacy  and safety of intravesical chondroitin sulphate for the  treatment of interstitial cystitis. BJU Int 2009;103:56-60. 32.   Nickel JC, Egerdie RB, Steinhoff G, et al. A multicenter,  randomized, double-blind, parallel group pilot evaluation  of the efficacy and safety of intravesical sodium chondroitin  sulfate versus vehicle control in patients with interstitial  cystitis/painful bladder syndrome. Urology 2010;76:804-9. 33.   Nickel JC, Hanno P, Kumar K, et al. Second multicenter,  randomized, double-blind, parallel-group evaluation of  effectiveness and safety of intravesical sodium chondroitin  sulfate compared with inactive vehicle control in subjects  with interstitial cystitis/bladder pain syndrome. Urology  2012;79:1220-4. 34.   Porru D, Leva F, Parmigiani A, et al. Impact of intravesical  hyaluronic acid and chondroitin sulfate on bladder  pain syndrome/interstitial cystitis. Int Urogynecol J  2012;23:1193-9. 35.   Cervigni M, Natale F, Nasta L, et al. Intravesical  hyaluronic acid and chondroitin sulphate for bladder pain  syndrome/interstitial cystitis: long-term treatment results.  Int Urogynecol J 2012;23:1187-92. 36.   Gülpınar O, Kayı ş  A, Süer E, et al. Clinical comparision  of intravesical hyaluronic acid and hyaluronic acid- chondroitin sulphate therapy for patients with bladder  pain syndrome/interstitital cystitis. Can Urol Assoc J  2014;8:E610-4. Cite this article as:  Cervigni M. Interstitial cystitis/ bladder pain syndrome and glycosaminoglycans replacement  therapy. Transl Androl Urol 2015;4(6):638-642. doi: 10.3978/ j.issn.2223-4683.2015.11.04 </p>
                                        
                                            <p>1. Transl Androl Urol  2015;4(6):638-642 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. Interstitial cystitis/bladder pain syndrome (IC/BPS) is a  debilitating chronic syndrome characterized by discomfort  or recurrent abdominal and pelvic pains in the absence  of urinary tract infections. Its symptomatology includes  discomfort, increased bladder pressure, sensitivity and  intense pain in the bladder and pelvic areas, increased  voiding frequency and urgency, or a combination of these  symptoms. The pain often worsens during menstruation  and may intensify during intercourse [National Institute of  Diabetes and Digestive and Kidney Diseases (NIDDK)].  It also worsens with bladder filling and is relieved after  bladder emptying (1). For these reasons, this pathology has a very negative  impact on quality of life (2).  This condition has a prevalence rate of 2.71% and 1.22%  in women and men, respectively, although these rates  depend on the definitions used (3). The etiology of IC/BPS  is still not well understood and different hypotheses have  Review Article Interstitial cystitis/bladder pain syndrome and glycosaminoglycans  replacement therapy Mauro Cervigni Interstitial Cystitis Referral Center, Catholic University, Rome, Italy Correspondence to:  Mauro Cervigni. Interstitial Cystitis Referral Center, Catholic University, Rome, Italy. Email: <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="bbd6dacec9d495d8dec9cdd2dcd5d2fbc9d695ced5d2d8dacfcf95d2cf95">[email&#160;protected]</a> Abstract:  Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic disease characterized  by discomfort or recurrent abdominal and pelvic pains in the absence of urinary tract infections. Its  symptomatology includes discomfort, increased bladder pressure, sensitivity and intense pain in the bladder  and pelvic areas, increased voiding frequency and urgency, or a combination of these symptoms. For these  reasons, this pathology has a very negative impact on quality of life. The etiology of IC/BPS is still not  well understood and different hypotheses have been formulated, including autoimmune processes, allergic  reactions, chronic bacterial infections, exposure to toxins or dietary elements, and psychosomatic factors.  The finding of an effective and specific therapy for IC/BPS remains a challenge for the scientific community  because of the lack of a consensus regarding the causes and the inherent difficulties in the diagnosis. The  last recent hypothesis is that IC/BPS could be pathophysiologically related to a disruption of the bladder  mucosa surface layer with consequent loss of glycosaminoglycans (GAGs). This class of mucopolysaccharides  has hydrorepellent properties and their alteration expose the urothelium to many urinary toxic agents. It  has been hypothesized that when these substances penetrate the bladder wall a chain is triggered in the  submucosa. In order to improve the integrity and function of the bladder lining, GAG layer replenishment  therapy is widely accepted as therapy for patients with IC/BPS who have poor or inadequate response to  conventional therapy. Currently, Chondroitin sulfate (CS), heparin, hyaluronic acid (HA), and pentosan  polysulfate (PPS), and combinations of two GAGs (CS and HA) are the available substances with different  effectiveness rates in patients with IC/BPS. There are four different commercially available products for  GAG replenishment including CS, heparin, HA and PPS. Each product has different concentrations and  dosage formulations. Recently, a combination of CS and HA is the latest commercially available product with  promising results. Keywords:  Bladder pain syndrome; interstitial cystitis (IC); glycosaminoglycan replacement (GAG replacement);  multimodal therapy Submitted Oct 26, 2015. Accepted for publication Oct 27, 2015. doi: 10.3978/j.issn.2223-4683.2015.11.04 View this article at:  http://dx.doi.org/10.3978/j.issn.2223-4683.2015.11.04 </p>
                                        
                                            <p>4. 641 Translational Andrology and Urology, Vol 4, No 6 December 2015 Transl Androl Urol  2015;4(6):638-642 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. the study criteria. There were 30 patients in the HA-CS    group (mean age: 48.47 years old) and 23 patients in the  HA group (mean age: 49.61 years old) (P&gt;0.05). The  initial PST was positive in 71.7% patients (38/53) overall  with no difference between groups (P&gt;0.05). Responses  for VAS, ICSI, Interstitial Cystitis Problem Index (ICPI),    24-hour frequency/nocturia statistically improved in both  groups at 6 months. There was no significant difference  in symptomatic improvement (P&gt;0.05). Eight patients had  mild adverse events (36). Conclusions HA and HA/CS therapy are effective treatment options  for patients with IC/BPS who had inadequate response to  conservative treatment, in the short term. IC/PBS remains a prevalent, but untreated disease  with a poorly understood pathophysiology. Nonetheless,  research suggests that (I) disruption of the bladder GAG/ proteoglycan layer, (II) upregulated immune/inflammatory  response, (III) neural upregulation, and (IV) pelvic floor  dysfunction may all play a role in the pathophysiology of  the disease. However, further randomized controlled studies with  a larger number of patients and a longer follow-up period  are needed to confirm these encouraging results and to  optimize the treatment protocol for a sustained long-term  therapeutic effect. Acknowledgements None. Footnote Conflicts of Interest : The author has no conflicts of interest to  declare. References 1.   Coelho MF, Rebola J. Cistite Intersticial Etiopatogenia e  Atitudes Terapêuticas. Acta Urológica 2003;20:19-24. 2.   van de Merwe JP, Nordling J, Bouchelouche P, et al.  Diagnostic criteria, classification, and nomenclature for  painful bladder syndrome/interstitial cystitis: an ESSIC  proposal. Eur Urol 2008;53:60-7. 3.   Clemens JQ, Link CL, Eggers PW, et al. Prevalence of  painful bladder symptoms and effect on quality of life  in black, Hispanic and white men and women. J Urol  2007;177:1390-4. 4.   Giannantoni A, Bini V, Dmochowski R, et al.  Contemporary management of the painful bladder: a  systematic review. Eur Urol 2012;61:29-53. 5.   Mahmoud MS. Bladder pain syndrome/interstitial cystitis: a  reappraisal for the clinician. J Reprod Med 2011;56:405-9. 6.   Bassi P, Costantini E, Foley S, et al. Glycosaminoglycan  therapy for bladder diseases: emerging new treatments.  Eur Urol 2011;Suppl 10:451-9. 7.   Iavazzo C, Athanasiou S, Pitsouni E, et al. Hyaluronic  acid: an effective alternative treatment of interstitial  cystitis, recurrent urinary tract infections, and hemorrhagic  cystitis? Eur Urol 2007;51:1534-40; discussion 1540-1. 8.   Parsons CL. Prostatitis, interstitial cystitis, chronic  pelvic pain, and urethral syndrome share a common  pathophysiology: lower urinary dysfunctional epithelium  and potassium recycling. Urology 2003;62:976-82. 9.   Hurst RE. Structure, function, and pathology of  proteoglycans and glycosaminoglycans in the urinary tract.  World J Urol 1994;12:3-10. 10.   Fall M, Baranowski AP, Elneil S, et al. EAU guidelines on  chronic pelvic pain. Eur Urol 2010;57:35-48. 11.   Parsons CL. The therapeutic role of sulfated  polysaccharides in the urinary bladder. Urol Clin North  Am 1994;21:93-100. 12.   Parsons CL, Forrest J, Nickel JC, et al. Effect of pentosan  polysulfate therapy on intravesical potassium sensitivity.  Urology 2002;59:329-33. 13.   Davis EL, El Khoudary SR, Talbott EO, et al. Safety  and efficacy of the use of intravesical and oral pentosan  polysulfate sodium for interstitial cystitis: a randomized  double-blind clinical trial. J Urol 2008;179:177-85. 14.   Mulholland SG, Hanno P, Parsons CL, et al. Pentosan  polysulfate sodium for therapy of interstitial cystitis. A  double-blind placebo-controlled clinical study. Urology  1990;35:552-8. 15.   Parsons CL, Benson G, Childs SJ, et al. A quantitatively  controlled method to study prospectively interstitial cystitis  and demonstrate the efficacy of pentosanpolysulfate. J  Urol 1993;150:845-8. 16.   La Rock DR, Sant GR. Intravesical therapies for  interstitial cystitis. In: Sant GR, editor. Interstitial Cystitis.  Philadelphia, PA: Lippincott-Raven, 1997. 17.   Holm-Bentzen M, Jacobsen F, Nerstrøm B, et al. A  prospective double-blind clinically controlled multicenter  trial of sodium pentosanpolysulfate in the treatment of  interstitial cystitis and related painful bladder disease. J  </p>
                                        
                                            <p>3. 640 Cervigni. IC/BPS and glycosaminoglycans replacement therapy Transl Androl Urol  2015;4(6):638-642 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. HA. For example in a double-blind, placebo-controlled,  multicentre clinical study with this GAG in different  preparations (40 or 200 mg/cc), no significant efficacy of  sodium hyaluronate compared to placebo was found for  interstitial cystitis (IC) patients. However, further details,  including patient selection, inclusion/exclusion criteria,  definition of improvement/success, are not available (27). In  the study of Daha  et al.  hydrodistention in combination with  HA with potassium chloride (KCl), in addition to sodium  chloride (NaCl), were used as a treatment of IC/BPS.    With the combined use of KCl and NaCl, pain was  improved by 62.5% and 71.48% respectively (28). HA does  not provide immediate relief of symptoms, as some time is  required before the onset of regeneration of the GAG layer.  By contrast, lidocaine (a local anesthetic) can reduce sensory  ending excitability in the bladder and help with the control  and immediate relief of pain and voiding frequency. For this  reason, Lv proposed a combined therapy that may lead to  an immediate relief of symptoms by addicting lidocaine to  HA. With this treatment, voiding frequency was reduced by  67.25% and pain was reduced by 70.82% (29). Chondroitin sulfate (CS) CS is another natural proteoglycan present in the GAG  layer of the bladder epithelium. Like HA, intravesical  instillation of this molecule has been proposed as  a treatment for patients with IC/BPS, to promote  regeneration of GAG in the bladder urothelium. Results  from a recent experiment revealed good control of urinary  symptoms and pain, suggesting that the use of this drug in  IC/BPS may be of benefit. Intravesical CS therapy efficiency  was evaluated by Steinhoff and colleagues in an open-label  12-month study. In this study, the authors treated 18 patients  with 40-mL instillations of CS 0.2% weekly for 4 weeks and  then monthly for 12 months. They found a response rate for  symptom improvement of 67% (30). In an uncontrolled open multicenter study of 53 IC  patients, instillations of CS 2% produced a 60% response  rate at 6 months (31). In contrast, a recently published RCT failed to show  superiority of CS 2.0% over control after 6 weeks of  treatment. In that study, most patients reported a clinical  benefit, but the difference between treatment and control  group was not statistically significant (32). According to the 2012 data of the Brazilian Ministry of  Health, the production of intravesical HA was stimulated by  instillation of CS; a substance that blocks the action of lytic  enzymes and stimulates proteoglycan synthesis by inducing  increased HA levels, thus reconstituting the urothelium. Nickel  et al.  conducted an interventional study by using  bladder hydrodistention with 20 mL of saline associated  with 2% CS, and found an improvement in pain and urinary  urgency of 47% and a decrease in voiding frequency by  51.8% (33). CS and HA A combination of two GAG contains CS (2.0%) and low  molecular weight HA (1.6%) is the latest available substance  for the GAG replenishment therapy. In an open-label single arm study by Porru and  colleagues, the efficiency of intravesical CS/HA combination  therapy was evaluated in IC/PBS patients. Twenty-two  patients with IC/BPS received intravesical instillations  (40 mL) of sodium HA 1.6% and CS 2.0% in 0.9% saline  solution (IALURIL ® ) (IBSA, Lugano, Switzerland) once  weekly for 8 weeks, then once every 2 weeks for the next    6 months. Parameters included visual analogue scale (VAS)  for pain and urgency, number of void per day, mean voiding  volume, Interstitial Cystitis Symptom Index (ICSI) and Pain  Urgency Frequency (PUF) questionnaire. The score for urgency was reduced from 6.5 to 3.6  (P=0.0001), with a reduction in pain scores from an  average of 5.6 to 3.2 (P=0.0001). The average urine  volume increased from 129.7 to 162 mL (P&lt;0.0001), with  a reduction in the number of voids in 24 hours, from 14 to    11.6 (P&lt;0.0001). The IC Symptom and Problem Index  decreased from 25.7 to 20.3 (P&lt;0.0001), and the PUF score,  from 18.7 to 12.8 (P&lt;0.0001) (34). Cervigni and colleagues reported the long-term results  of intravesical CS/HA therapy in 12 IC/BPS patients  refractory to other treatments. They used a combination of  HA 1.6% and CS 2.0% over a period of 3 years assessing  symptoms and quality of life using a visual analogue  scale, 3-day voiding diaries and validated questionnaires.  Improvements in bladder function were sustained for    3 years (mean number of daily voids decreased from 17.8 at    baseline to 15.5 at 9 months and 11.9 at 3 years, and mean  volume per void from 136.8 mL at baseline to 143.9 mL  at 9 months and 180.9 mL at 3 years). Quality of life  assessments confirmed these improvements (35). Ömer Gülpınarite studied 53 BPS IC patients with  inadequate clinical response after 6 months of conservative  treatment comparing for the first time intravesical HA/CS    combination and intravesical HA. In total, 53 patients met  </p>
                                        
                                            <p>2. 639 Translational Andrology and Urology, Vol 4, No 6 December 2015 Transl Androl Urol  2015;4(6):638-642 www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. been formulated, including autoimmune processes, allergic  reactions, chronic bacterial infections, exposure to toxins or  dietary elements, and psychosomatic factors (4,5). The finding of an effective and specific therapy for IC/BPS    remains a challenge for the scientific community because  of the lack of a consensus regarding the causes and the  inherent difficulties in the diagnosis. The last recent  hypothesis is that IC/BPS could be pathophysiologically  related to a disruption of the bladder mucosa surface layer  with consequent loss of glycosaminoglycans (GAGs). This  class of mucopolysaccharides has hydrorepellent properties  and their alteration expose the urothelium to many urinary  toxic agents. It has been hypothesized that when these  substances penetrate the bladder wall a chain is triggered in  the submucosa. Here nerve terminals produce inflammatory  mediators causing mast cell degranulation and histamine  secretion with consequent vasodilatation and inflammatory  exudate. The consequence of this inflammatory response  is the stimulation of C fibers with mast cell activation and  histamine release. This produce consequent bladder pain  and release of neuropetides with a consequent damage to  the mucosa and fibrosis of the submucosa (6-8). The major  classes of GAG include hyaluronic acid (HA), heparin  sulphate, heparin, chondroitin 4-sulphate, chondroitin  6-sulphate, dermatan sulphate and keratan sulphate (9).  In order to improve  the integrity and function of the  bladder lining, GAG layer replenishment therapy is widely  accepted as therapy for patients with IC/BPS who have  poor or inadequate response to conventional therapy (10).  Currently, chondroitin sulfate (CS), heparin, HA, and  pentosan polysulfate (PPS), and combinations of two GAGs  (CS and HA) are the available substances with different  effectiveness rates in patients with IC/BPS. There are four different commercially available products  for GAG replenishment including CS, heparin, HA and  PPS. Each product has different concentrations and dosage  formulations. Recently, a combination of CS and HA is the  latest commercially available product. Sodium pentosan polysulfate (PPS) PPS is a semi-synthetic, sulfated polysaccharide, which is  chemically and structurally similar to heparin and GAG. A  proposed mechanism is that the drug replaces the damaged  parts of the GAG layer that lines the bladder (11). It has  been reported that PPS reduces bladder permeability based  on the potassium sensitivity test (12). Currently, PPS is the  only oral therapy approved by the FDA for IC/PBS (13).    However, randomized controlled trials (RCTs) have shown  mixed results in its efficacy. Mulholland and Parsons  separately reported significantly improved pain and urgency  symptoms from baseline at 3-month follow-up (14,15).  La Rock and Sant (16) suggested that in comparison with  oral therapy, intravesical sodium pentosan polysulphate  (SPP) therapy promotes direct absorption of the drug by  the bladder. Conversely, Holm-Bentzen  et al.  failed to  demonstrate any difference at 4-month follow-up compared  to placebo (17). Increasing treatment doses does not appear  to improve efficacy from the 100 mg 3 times a day (TID)  dosing. Diarrhea, abdominal pain, and rectal bleeding are  the most common side effects and have been found to be  dose-related. Alopecia was also noted in 5% of patients in  one study (18). High-quality evidence demonstrates mixed  support for this therapy. Therefore, given the moderate side  effect profile, PPS is recommended as a second-line therapy  for IC/PBS (19). Hyaluronic acid (HA) Intravesical HA was the first GAG substance used for IC/PBS.    Morales  et al.  published the first study in 1996; they found  a complete or partial response rate of 71% for up to    1 year (20). In patients with IC/BPS, the concentration of  this acid is decreased and urothelial permeability toward  potassium compounds is increased, causing an increase  in bladder pain. HA inhibits leukocyte chemotactic and  phagocytic functions, and reduces the permeability of the  synovial membrane (21). HA acts on urothelial cells in three  distinct ways: by increasing secretion of GAG enzymes;  this leads to increased GAG secretion, leading to restored  homoeostasis and eventual normal GAG barrier production.  HA through a direct physicochemical interaction with the  cells’ surface decreases the permeability of the urothelium.  HA acts on the third pathway by decreasing secretion  of pro-inflammatory cytokines IL-6 and IL-8 from the  urothelial cells, decreasing immune cell infiltration to the  urothelium and decreasing inflammation (22). HA has been  the subject of multiple studies and has shown a wide range  of symptom improvement, from 30% to 85% (23-25).    In 2011 Engelhardt and his collaborators reported their  long-term results of intravesical HA therapy; they observed  a 50% complete bladder symptom remission at the 5-year  follow-up without any additional therapy, while 41.7%  with symptom recurrence improved with HA maintenance  therapy (26). Not all the studies have shown a significant effect of  </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1250</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">959</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">291</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    4
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">13</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">12</span>
                                                    www.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">1</span>
                                                    www.novotrade.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1472 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1487 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/22/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"><h6 class="mb-1">Glycosaminoglycan Therapy for Bladder Diseases</h6></a>
            <small class="text-muted">
                1384 Views . <timeago class="timeago" datetime="2019-10-31 13:30:10.980936"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1463 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1303 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1361 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/26/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"><h6 class="mb-1">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h6></a>
            <small class="text-muted">
                1298 Views . <timeago class="timeago" datetime="2019-10-31 13:36:14.959707"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1413 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1367 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1488 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/30/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1220 Views . <timeago class="timeago" datetime="2019-10-31 13:38:52.835202"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/31/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"><h6 class="mb-1">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h6></a>
            <small class="text-muted">
                1387 Views . <timeago class="timeago" datetime="2019-10-31 13:39:08.628954"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/33/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"><h6 class="mb-1">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h6></a>
            <small class="text-muted">
                1387 Views . <timeago class="timeago" datetime="2019-10-31 13:40:52.836690"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1309 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/35/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"><h6 class="mb-1">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h6></a>
            <small class="text-muted">
                1299 Views . <timeago class="timeago" datetime="2019-10-31 13:45:59.326213"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1357 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/37/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) for the treatment of female recurrent urinary tract infections- bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1239 Views . <timeago class="timeago" datetime="2019-10-31 13:46:36.042595"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3284 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3044 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2846 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2643 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2438 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2324 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2321 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2209 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2038 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1773 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1708 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1690 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1618 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1612 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1605 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Blog</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="670e090108270f0514490f12">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:04:18 GMT -->
</html>
    
    
